Nothing Special   »   [go: up one dir, main page]

Van Belle et al., 2011 - Google Patents

Type 1 diabetes: etiology, immunology, and therapeutic strategies

Van Belle et al., 2011

View HTML @Full View
Document ID
2770106434842627380
Author
Van Belle T
Coppieters K
Von Herrath M
Publication year
Publication venue
Physiological reviews

External Links

Snippet

Type 1 diabetes (T1D) is a chronic autoimmune disease in which destruction or damaging of the beta-cells in the islets of Langerhans results in insulin deficiency and hyperglycemia. We only know for sure that autoimmunity is the predominant effector mechanism of T1D, but may …
Continue reading at journals.physiology.org (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Similar Documents

Publication Publication Date Title
Van Belle et al. Type 1 diabetes: etiology, immunology, and therapeutic strategies
Herold et al. Type 1 diabetes: translating mechanistic observations into effective clinical outcomes
Staeva-Vieira et al. Translational mini-review series on type 1 diabetes: immune-based therapeutic approaches for type 1 diabetes
Casares et al. Down-regulation of diabetogenic CD4+ T cells by a soluble dimeric peptide–MHC class II chimera
AU2002243905B2 (en) Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
Roep et al. Immune modulation in humans: implications for type 1 diabetes mellitus
Noorchashm et al. B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice
Bresson et al. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs
Waldron-Lynch et al. Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes
Wang et al. Breach of tolerance: primary biliary cirrhosis
Chatenoud Immune therapy for type 1 diabetes mellitus—what is unique about anti-CD3 antibodies?
You et al. Transforming growth factor‐β and T‐cell‐mediated immunoregulation in the control of autoimmune diabetes
Balasa et al. IL-10 impacts autoimmune diabetes via a CD8+ T cell pathway circumventing the requirement for CD4+ T and B lymphocytes
Marfil-Garza et al. Progress in translational regulatory T cell therapies for type 1 diabetes and islet transplantation
Ludvigsson Therapies to preserve β-cell function in type 1 diabetes
EP3151853A2 (en) Novel combinations for antigen based therapy
Krishnamurthy et al. Analysis of antigen specific T cells in diabetes–Lessons from pre-clinical studies and early clinical trials
Bresson et al. Immunotherapy for the prevention and treatment of type 1 diabetes: optimizing the path from bench to bedside
Leng et al. Elevated CXCL12 expression in the bone marrow of NOD mice is associated with altered T cell and stem cell trafficking and diabetes development
Sewell et al. Therapeutic strategies in common variable immunodeficiency
Li et al. Harnessing memory adaptive regulatory T cells to control autoimmunity in type 1 diabetes
CA3086632A1 (en) Clozapine for the treatment of a immunoglobulin driven b cell disease
Costello et al. Development of transplant immunosuppressive agents–considerations in the use of animal models
Lin et al. Reversal of type 1 diabetes by a new MHC II‐peptide chimera:“Single‐epitope‐mediated suppression” to stabilize a polyclonal autoimmune T‐cell process
WO2021019249A1 (en) Clozapine for use in treating pathogenic immunoglobulin driven b cell disease